ALK and non-small cell lung carcinoma: In patients with ALK-positive NSCLC, crizotinib, an adenosine triphosphate (ATP)-competitive, small-molecule, multi-targeted tyrosine kinase inhibitor (TKI), has demonstrated promising efficacy in many clinical studies, both in first-line and non–first-line settings [3–5].